Our latest research report entitled Automated Insulin Delivery System Market (by disease type (type I diabetes, and type II diabetes), end user (hospital pharmacies, retail pharmacies, and diabetes clinics)) provides complete and deep insights into the market dynamics and growth of automated insulin delivery system. Latest information on market risks, industry chain structure automated insulin delivery system cost structure and opportunities are offered in this report. The past, present and forecast market information will lead to investment feasibility by studying the essential automated insulin delivery system growth factors. According to the report, the global automated insulin delivery system market is projected to grow at a CAGR of 8.0% over the forecast period of 2019-2025.
Ask for Sample Copy of Research Report with Table of Content @ https://www.infiniumglobalresearch.com/reports/sample-request/6058
Automated insulin delivery is also known as a hybrid closed loop, artificial pancreas, bionic pancreas, and predictive low glucose suspend. The objective of an automated insulin delivery system is using continuous glucose monitors (CGMs) and smart algorithms that automatically decide and adjust insulin delivery via a pump. The aim of this product is to reduce/eradicate hypoglycemia, remove user input from insulin dosing, improve time-in-range, and reduce hyperglycemia. Insulin is the hormone that notifies the cells to take sugar from the blood and utilize it as an energy source. In type 1 diabetes, the immune system destroys beta cells in the pancreas, which makes insulin. In the absence of insulin, there is an escalation in blood sugar levels, resulting in a diabetic coma, and the body burns fat stores and muscle for energy. Thus, in order to maintain blood sugar levels in people with type 1 diabetes, it is necessary to monitor their blood sugar throughout the day continuously. The automated insulin delivery system relies on a transmitter which is attached to a tiny needle inserted into the skin that continuously tracks glucose levels, a pump that delivers accurate doses of insulin as they are required via a separate catheter inserted into the skin, and a computer chip that uses data from both to upgrade the delivery of insulin. The automated insulin delivery system allows people with type 1 diabetes significant freedom to live their lives without having to manually and constantly monitor baseline glucose levels and deliver insulin.
Rising Prevalence of Diabetes Worldwide is the Major Growth Factor for the Automated Insulin Delivery System Market
The rising prevalence of diabetes worldwide is the major growth factor for the automated insulin delivery system market. According to WHO reports the number of a diabetic patient has increased from 108 million in 1980 to 422 million in 2014, these rising numbers are augmenting the demand for advanced insulin delivery systems for the hassle-free insulin uptake. Moreover, increasing research and development activities for the production of innovative insulin delivery systems and increasing awareness campaigns by various companies are further boosting the growth of the market. However, technology snags may limit the adoption of an automated insulin delivery system. Difficulties with the calibration of a glucose sensor, sensor durability, skin related issues can restrict the use of an automated insulin delivery system. On the other hand, lenient regulatory approval and technical clarity for the use of devices among people can provide a better opportunity for the growth of the market.
North America Holds the Top Position in the Automated Insulin Delivery System Market
Region-wise automated insulin delivery system market segmented into North America, Europe, Asia Pacific and Rest of the World. Currently, North America holds the top position in the automated insulin delivery system market. The presence of top manufacturers and large investment in R&D for upgradation of existing insulin pumps and new product development are contributing to the growth of this region. European market expected to grow with a steady rate in the forecast year. In the near future developing countries in Asia-Pacific like India, China and Japan expected to grow with a high CAGR. Large diabetic patient pool and heavy investment in the healthcare sector are fuelling the growth of the market.
Automated Insulin Delivery System Market: Segmentation
The report on global automated insulin delivery system market covers segments such as disease type, and end user. On the basis of disease type, the sub-markets include type I diabetes, and type II diabetes. On the basis of end user, the sub-markets include hospital pharmacies, retail pharmacies, and diabetes clinics.
Automated Insulin Delivery System Market: Competitive Landscape
The report provides profiles of the companies in the market such as Medtronic plc, Eli Lilly and Company, Tandem Diabetes Care, Inc., Insulet Corporation, Bigfoot Biomedical, Inc., and Other companies.
Browse Detailed TOC, Description, and Companies Mentioned in Report @ https://www.infiniumglobalresearch.com/healthcare-medical-devices/global-automated-insulin-delivery-system-market
Reasons to Buy this Report:
- Comprehensive analysis of global as well as regional markets of the automated insulin delivery system.
- Complete coverage of all the product type and applications segments to analyze the trends, developments, and forecast of market size up to 2025.
- Comprehensive analysis of the companies operating in this market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and the latest developments of the company.
- Infinium Global Research- Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.